Tina Nghiem is a Site Engagement Lead at AstraZeneca Pharmaceuticals, where she plays a pivotal role in managing the Partners in Care Network. Since joining AstraZeneca in 2023, Tina has collaborated closely with sites to alleviate site burden and enhance site engagement across AstraZeneca clinical trials.

Prior to joining AstraZeneca, Tina spent more than 10 years in oncology clinical research. Most recently, she worked at an early phase research site, where she experienced firsthand the importance of site-sponsor partnerships in driving clinical trials.

Karla Sanchez leads a team of subject matter experts at CDP, supporting the Healthcare sector across a broad range of bioengineering specialties. With over thirteen years of experience in medical device development, she brings technical depth and strategic insight to complex health innovation projects. For the past six years, Karla has focused on drug delivery, with particular expertise in targeting the central nervous system (CNS). She leads efforts in drug delivery to the brain, working at the intersection of biology, engineering, and clinical need to overcome barriers to effective CNS therapies. She holds a PhD focused on the distribution of blood and cerebrospinal fluid in the brain and spinal cord, and has collaborated with clinicians and academics to develop physiological models of the brain, kidneys and lungs.

Karla is also an honorary researcher at Imperial College London, maintaining active links with academia and providing guidance to postgraduate students.

Fran has over 5 years of experience in drug delivery device design from concept generation to design verification testing and manufacturing scale-up, with a focus on injection devices. She has led multiple drug delivery projects, from design of novel electromechanical injectors through to due diligence of On-Body Delivery systems. Fran forms part of Cambridge Design Partnership’s core sustainability group, where she is responsible for identifying opportunities for sustainable innovation within the drug delivery sector. She has a master's degree in Mechanical and Bio-Engineering from the University of Cambridge.

TBA

TBA

Dr. Suri is a Data Scientist with 7+ years of experience in research and development. Her work at Gilead on building foundational and industry-leading AI capabilities for clinical trial design and execution includes co-developing advanced algorithms for country and site selection, and enrollment forecasting, which are critical to optimizing clinical study feasibility. She holds a PhD in Electrical and Computer Engineering from the University of Pittsburgh and is passionate about wearable technology and digital health. Dr. Suri has presented her work at prestigious venues such as the Global Hepatitis Summit, Gerontological Society of America Annual Meeting, and has been invited to speak at leading conferences including BioTechX, HITLAB, and ISPE. With a research background spanning gait and mobility, robotic sciences, and neuroimaging, she has built and applied machine learning pipelines to study disease-risk patterns. She is the author of 12+ peer-reviewed journal articles, which have collectively garnered over 1,000 citations, reflecting the significant impact and recognition of her work within the scientific community.

TBA

Łukasz Koroniak (Luke) is a Global Biomaterial Director Drug Delivery Solutions at dsm-firmenich, where he is focused on extending application of our portfolio including proprietary, biodegradable TheraPEA™ platform in the development of long-acting therapies. For the past 15 years at dsm-firmenich, Luke has been a part of innovation and business teams focused on development and commercialization of novel long-acting therapies. These efforts have led to commercial launches of partner products in cardiovascular, and more recently, a phase I/II development of novel product in ophthalmic space.

Luke holds a PhD in Organic Chemistry from University of Florida and EMBA from Alto University. In his 20-year tenure, he has developed a broad experience in drug discovery, medicinal chemistry, drug delivery and has authored several scientific publications and patents.